archived version — not current

This is a permanent, read-only archive of this profile's public content as it existed on 2026-09-23. It does not reflect the current, live profile. View the current profile.

Teduglutide

Snapshot captured 2026-09-23 — Published content materially edited

Overview

Teduglutide is a GLP-2 analog studied in short bowel syndrome and intestinal failure. The clinical question concerns outcomes such as parenteral support and patient experience in defined populations.

Evidence quality

WPF’s atlas includes pediatric case reports, observational cohorts of adults, and monitoring guidance for people receiving teduglutide. These sources can inform questions about long-term care, but a case report or observational association cannot alone establish the size of a causal treatment effect.

Safety concerns

This Directory entry has no published source-linked citations or jurisdiction-specific regulatory records. Adults and children, differing underlying anatomy, parenteral-support outcomes, and safety monitoring must be assessed separately against primary and official sources.

Citations as of this version

Regulatory status as of this version

European Union — EMA: approved — Revestive (teduglutide) is indicated for the treatment of patients 4 months corrected gestational age and above with Short Bowel Syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery. (Per the current SmPC Section 4.1; supersedes the older '1 year and above' figure still shown in the EMA overview page's summary info box as of this research.)
United States — FDA: approved — GATTEX (teduglutide) is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support.

Content hash: f4bbb2e6b756319741a7dc8d2dee1fb65fc97673a267a4ee75ae2827e88dd454

All archived versions